Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Submit your nominations for the Fierce CRO Awards
fatty liver disease
Research
Researchers ID potential MASH target by disrupting mouse gene
When the Nwd1 gene was disrupted, the rodents’ liver cells became enlarged with fat molecules and their livers became covered in scar tissue.
Darren Incorvaia
Mar 13, 2025 1:52pm
Inventiva lays off 50% of staff to go all-in on MASH drug
Feb 11, 2025 7:30am
Viking liver disease drug reduces fibrosis in final ph. 2 data
Nov 20, 2024 3:20pm
Aligos MASH prospect slashes liver fat in phase 2
Sep 19, 2024 1:00pm
Viking's MASH drug scores where Madrigal's didn't
Jun 4, 2024 1:51pm
Boehringer signs $1.3B MASH collab with RNA biotech Ochre
Apr 22, 2024 8:45am
